JP2011505381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505381A5 JP2011505381A5 JP2010536228A JP2010536228A JP2011505381A5 JP 2011505381 A5 JP2011505381 A5 JP 2011505381A5 JP 2010536228 A JP2010536228 A JP 2010536228A JP 2010536228 A JP2010536228 A JP 2010536228A JP 2011505381 A5 JP2011505381 A5 JP 2011505381A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- seq
- antibody
- segment
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99167907P | 2007-11-30 | 2007-11-30 | |
| US60/991,679 | 2007-11-30 | ||
| PCT/US2008/085196 WO2009073631A2 (en) | 2007-11-30 | 2008-12-01 | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505381A JP2011505381A (ja) | 2011-02-24 |
| JP2011505381A5 true JP2011505381A5 (https=) | 2012-01-26 |
| JP5781765B2 JP5781765B2 (ja) | 2015-09-24 |
Family
ID=40527381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536228A Expired - Fee Related JP5781765B2 (ja) | 2007-11-30 | 2008-12-01 | シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8044181B2 (https=) |
| EP (1) | EP2220117A2 (https=) |
| JP (1) | JP5781765B2 (https=) |
| KR (1) | KR20100097719A (https=) |
| CN (1) | CN101910197B (https=) |
| AU (1) | AU2008333985B2 (https=) |
| BR (1) | BRPI0819598A2 (https=) |
| CA (1) | CA2706732A1 (https=) |
| EA (1) | EA201000903A1 (https=) |
| IL (1) | IL206036A0 (https=) |
| MX (1) | MX2010005871A (https=) |
| NZ (1) | NZ586357A (https=) |
| SG (1) | SG186017A1 (https=) |
| WO (1) | WO2009073631A2 (https=) |
| ZA (1) | ZA201003852B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| BRPI0513826A2 (pt) | 2004-07-26 | 2010-06-22 | Dow Global Technologies Inc | processo para expressão de proteìna melhorada através de engenharia de cepa |
| US9394571B2 (en) * | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9580719B2 (en) * | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| EA020544B1 (ru) | 2008-01-10 | 2014-12-30 | Шионоги Энд Ко., Лтд. | АНТИТЕЛА ПРОТИВ PcrV |
| CA2751433A1 (en) * | 2009-02-04 | 2010-08-12 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
| SG174225A1 (en) * | 2009-03-11 | 2011-10-28 | Shionogi & Co | Humanized pcrv antibody having anti-pseudomonal activity |
| WO2011087799A1 (en) * | 2009-12-22 | 2011-07-21 | Kalobios Pharmaceuticals, Inc. | A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
| WO2012012571A1 (en) | 2010-07-21 | 2012-01-26 | Hans Zassenhaus | Biolayer interferometry measurement of biological targets |
| RU2014100111A (ru) | 2011-06-10 | 2015-07-20 | МЕДИММЬЮН, ЭлЭлСи | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ |
| HRP20201370T1 (hr) * | 2011-11-07 | 2020-11-27 | Medimmune Limited | Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule |
| EP2820043B1 (en) | 2012-03-02 | 2020-01-15 | Ablynx N.V. | Biparatopic pseudomonas aeruginosa pcrv binding single variable domain antibodies |
| BR112015010240A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Ltd | Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas |
| ES2846881T3 (es) | 2015-05-01 | 2021-07-30 | Inhibrx Inc | Moléculas que se dirigen al sistema de secreción de tipo III |
| CA2991634C (en) | 2015-07-16 | 2026-03-17 | Inhibrx Biosciences, Inc. | Multivalent and multispecific dr5-binding fusion proteins |
| SG11201809778TA (en) | 2016-05-05 | 2018-12-28 | Univ Pennsylvania | Dna antibody constructs for use against pseudomonas aeruginosa |
| EA202091984A1 (ru) | 2018-03-14 | 2021-02-18 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 |
| MX2021001305A (es) | 2018-08-01 | 2021-06-23 | Cephalon Inc | Anticuerpos anti-cxcr2 y usos de los mismos. |
| EP3983015A1 (en) * | 2019-06-11 | 2022-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
| CN118620074A (zh) * | 2020-06-01 | 2024-09-10 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US108565A (en) * | 1870-10-25 | Improvement in snow-plows | ||
| US134098A (en) * | 1872-12-17 | Improvement in gage-cocks | ||
| US225552A (en) * | 1880-03-16 | Disintegrating-mill | ||
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5219998A (en) * | 1990-06-04 | 1993-06-15 | Levin Robert H | Yeast-derived epidermal growth factor |
| GB9012995D0 (en) * | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| WO1998002462A1 (en) | 1996-07-16 | 1998-01-22 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Immunoglobulin superfamily domains and fragments with increased solubility |
| US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| EP1666058B1 (en) * | 1998-11-25 | 2011-12-28 | MCW Research Foundation, Incorporated | Method of diagnosing a Pseudomonas aeruginosa infection |
| DE19918418C1 (de) * | 1999-04-23 | 2000-10-19 | Siegfried Mueller | Pflanzvorrichtung mit Halterung |
| WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| WO2002064161A2 (en) * | 2001-01-26 | 2002-08-22 | Mcw Research Foundation, Inc. | Method and compositions for immunization with the pseudomonas v antigen |
| CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| ATE458006T1 (de) * | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| EP1761561B1 (en) * | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| PT2343380T (pt) * | 2004-11-16 | 2019-09-18 | Humanigen Inc | Permuta de cassetes da região variável de imunoglobulina |
| EP1915394B1 (en) | 2005-05-20 | 2021-01-27 | Lonza Biologics plc. | High-level expression of recombinant antibody in a mammalian host cell |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| CA2613691A1 (en) | 2005-07-05 | 2007-01-11 | Baker Medical Research Institute | Anticoagulation agent and uses thereof |
| EP1987066B1 (en) | 2006-02-22 | 2010-12-29 | University of Zürich | Methods for treating demyelinating diseases |
| US7649083B2 (en) | 2006-06-02 | 2010-01-19 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| EP2386577A3 (en) | 2006-06-21 | 2012-05-02 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof |
-
2008
- 2008-12-01 BR BRPI0819598A patent/BRPI0819598A2/pt not_active IP Right Cessation
- 2008-12-01 SG SG2012085239A patent/SG186017A1/en unknown
- 2008-12-01 AU AU2008333985A patent/AU2008333985B2/en not_active Ceased
- 2008-12-01 NZ NZ586357A patent/NZ586357A/xx not_active IP Right Cessation
- 2008-12-01 CN CN200880124705.7A patent/CN101910197B/zh not_active Expired - Fee Related
- 2008-12-01 CA CA2706732A patent/CA2706732A1/en active Pending
- 2008-12-01 KR KR1020107014345A patent/KR20100097719A/ko not_active Ceased
- 2008-12-01 EA EA201000903A patent/EA201000903A1/ru unknown
- 2008-12-01 MX MX2010005871A patent/MX2010005871A/es active IP Right Grant
- 2008-12-01 JP JP2010536228A patent/JP5781765B2/ja not_active Expired - Fee Related
- 2008-12-01 EP EP08856948A patent/EP2220117A2/en not_active Ceased
- 2008-12-01 WO PCT/US2008/085196 patent/WO2009073631A2/en not_active Ceased
- 2008-12-01 US US12/325,806 patent/US8044181B2/en not_active Expired - Fee Related
-
2010
- 2010-05-27 IL IL206036A patent/IL206036A0/en unknown
- 2010-05-28 ZA ZA2010/03852A patent/ZA201003852B/en unknown
-
2011
- 2011-10-11 US US13/271,146 patent/US8877191B2/en not_active Expired - Fee Related
-
2014
- 2014-10-08 US US14/509,437 patent/US20150030614A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5781765B2 (ja) | シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体 | |
| JP2011505381A5 (https=) | ||
| US12428473B2 (en) | Combination therapies using anti-pseudomonas PSL and PCRV binding molecules | |
| US8653242B2 (en) | Therapeutic antibodies against flagellated Pseudomonas aeruginosa | |
| US20150284450A1 (en) | Combination therapies using anti-pseudomonas psl and pcrv binding molecules | |
| US20100272736A1 (en) | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection | |
| HK1201453B (en) | Combination therapies using anti- pseudomonas psl and pcrv binding molecules | |
| NZ722379B2 (en) | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |